Found this information in: Diabetes.co.uk.
A new class of cholesterol drugs is being developed. Preliminary research suggests that the drugs reduce levels of "bad" cholesterol more effectively than anything currently available, and significantly reduce the risk of heart attacks and stroke. The drugs have the potential to be more effective than statins, which are the currently the most common cholesterol-lowering drug. But it has not been proved that statins reduce the risk of heart disease in stroke. Furthermore, recent research has indicated that statins may increase the risk of type 2 diabetes. Heart diseases is one of the most common diabetic complications. One study concluded that statins increase the risk of type 2 diabetes by 46 per cent. The new drugs, known as evulocumab and alirocumab, reduce levels of low-density lipoprotein in the body, potentially by as much as 60 per cent. The drugs could be more effective than statins. Both drugs inhibit PCSK9, which is a protein responsible for the regulation of cholesterol.